3681.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 10:43):

Stats
Dzisiejszy wolumen	46 500.00
Średni wolumen	203 956
Kapitalizacja rynkowa	2.04B
EPS	HKD0 ( 2024-03-25 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-7.31
ATR14	HKD0.0280 (1.47%)

SinoMab BioScience Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SinoMab BioScience Ltd Finanse

Annual	2023
Przychody:	HKD1.37M
Zysk brutto:	HKD422 000 (30.92 %)
EPS:	HKD-0.240

FY	2023
Przychody:	HKD1.37M
Zysk brutto:	HKD422 000 (30.92 %)
EPS:	HKD-0.240

FY	2022
Przychody:	HKD4.03M
Zysk brutto:	HKD4.03M (100.00 %)
EPS:	HKD-0.290

FY	2021
Przychody:	HKD25.91M
Zysk brutto:	HKD0.00 (0.00 %)
EPS:	HKD-0.286

Financial Reports:

No articles found.

SinoMab BioScience Ltd

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.